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Background: To identify predictive factors of radiation-induced skin toxicity in breast cancer patients by the
analysis of dosimetric and clinical factors.
Methods: 339 patients treated between January 2007 and December 2010 are included in the present analysis.
Whole breast irradiation was delivered with Conventional Fractionation (CF) (50Gy, 2.0/day, 25 fractions) and
moderate Hypofractionated Schedule (HS) (44Gy, 2.75Gy/day, 16 fractions) followed by tumour bed boost. The
impact of patient clinical features, systemic treatments and, in particular, dose inhomogeneities on the occurrence
of different levels of skin reaction has been retrospectively evaluated.
Results: G2 and G3 acute skin toxicity were 42% and 13% in CF patients and 30% and 7.5% in HS patients
respectively. The retrieval and revaluation of 200 treatment plans showed a strong correlation between areas close
to the skin surface, with inhomogeneities >107% of the prescribed dose, and the desquamation areas as described
in the clinical records.
Conclusions: In our experience dose inhomogeneity underneath G2 – G3 skin reactions seems to be the most
important predictor for acute skin damage and in these patients more complex treatment techniques should be
considered to avoid skin damage. Genetic polymorphisms too have to be investigated as possible promising
candidates for predicting acute skin reactions.Background
Radiation Therapy (RT) has gained an established role in
the treatment of breast cancer either as chest wall irra-
diation for high risk patients after modified radical mast-
ectomy, or as whole breast irradiation for patients after a
breast conserving surgery (BCS). The challenge now is
to minimise the morbidity caused by treatment without
losing its efficacy and to select patients at risk of deve-
loping skin toxicity who deserve more complex treat-
ment techniques able to reduce this problem. Acute and* Correspondence: sara_terenzi@faswebnet.it
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reproduction in any medium, provided the orchronic toxicities have been reported in patients after
breast or chest wall RT [1,2]. Postoperative RT for breast
cancer patients is delivered using conventional tangential
fields with dose inhomogeneities resulting in an excess
irradiation of breast tissue. Three-dimensional conformal
Radiation Therapy (3D-CRT), IMRT and Tomotherapy
are associated with relatively lower risks of toxicity com-
pared with 2D technique [3,4]. Skin toxicity can lead to
temporary or permanent cessation of treatment, pain, oc-
casionally systemic infection, and may cause permanent
skin changes. This problem may probably be reduced im-
proving dose conformity and dose homogeneity within
the irradiated area and in close proximity of the skin
surface in spite of the fact that complex techniques asal Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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dies [5] have addressed this item, but off-axis dose inho-
mogeneities have rarely been considered although it has
been suggested by some Authors [6].
With the limits of retrospective studies, some data
have suggested that dose inhomogeneties (V > 107%)
was a significant predictor of RT-induced skin toxicity
on the occurrence of severe skin reactions [7,8].
The aim of our analysis is to try to relate “hot spot”
volumes, sites and amount of dose inhomogeneities to
skin toxicity in a set of patients who underwent 3D
conformal irradiation whose 3D treatment plans were
retrieved and revaluated to calculate the volumes of
Planning Target Volume and Treated Volume receiving
more than 107% of the prescribed dose.Methods
Characteristics of patients and data collection
Between January 2007 and December 2010, 339 eva-
luable patients for the present analysis, with histological
confirmed early breast cancer (pT1-2, pN0-1), were
referred, for post-operative treatment after breast con-
servative surgery, to our Radiation Therapy Unit. The
main clinical features of these patients and of the tu-
mours are reported in the Table 1. All of the patients
provided an informed consent for breast irradiation. Pa-
tients who received prior breast irradiation, presented
bilateral breast cancer, affected by seromas, wound
infection, connective tissue disorders were excluded by
the present evaluation.
All of these patients underwent a clinical examination
before irradiation, weekly during the treatment course
and one week after the end of treatment, every month
for three months and at regular time intervals (every
three months) afterwards. One hundred and twenty six
patients received adjuvant chemotherapy after surgery
and before RT. Hormone therapy (tamoxifen or aroma-
tase inhibitors) were prescribed to 247 patients. Written
informed consent was obtained from the patients for
the purpose of this report as well as it concerns any ac-
companying image. Our Institutional Ethic Committee
(Comitato Etico Indipendente, Fondazione Policlinico
Tor Vergata, Roma) approved this study (protocol num-
ber 104/12).Total dose and fractionation
Whole breast irradiation was delivered with Conven-
tional Fractionation (CF) in 141 patients (50 Gy, 2 Gy/
day in 25 fractions) and moderate Hypofractionated
Schedule (HS) in 198 ones (44 Gy, 2.75 Gy/day in 16
fractions) followed by an electron tumour bed boost
(10–16 Gy, 2 Gy/day in 5–8 fractions or 9–15 Gy, 3 Gy/
day in 3–5 fractions).Biological equivalent dose
The biologically effective doses (BED) were calculated
assuming 4 Gy α/β ratio (tumour control), 10 Gy (acute
responding normal tissues) [9].
Differences in fractionation and overall treatment time
were taken into account using the following formula:
BED = (n·d) (1+d/(α/β))-(ln2/(α·Tpk )·(T-Tk).
Only for the CF and for tumour control the time fac-
tor (2nd addendum in the above equation) has been
taken into account. BEDs for HS was calculated assum-
ing zero as time factor [9]. Description of the parameters
used in the above formula are detailed in the Appendix.
Localization and planning
Planning CT scans (5 mm slice thickness) from the level
of the larynx to the upper abdomen, including both
lungs, were obtained in the supine or prone position
depending on patient tolerance and anatomy. Women
in supine set-up were positioned using a “wing-board”
(BIONIX Development Corporation, Toledo, Ohio) with
both arms raised above their head. Prone patients were
positioned using a commercially available immobilization
device (CIVCO, Orange City, USA).
CT data were transferred to Precise PlanW (Elekta,
Crawley, United Kingdom). Clinical Target Volume
(CTV) included whole breast tissue and was expanded by
10 mm, but within 5 mm from the skin surface, to create
the planned target volume (PTV). Organs at Risk (OARs),
lung and heart, were contoured according to the 50 and
62 International Commission on Radiations Units and
Measurements Reports Recommendations (ICRU) [10,11].
3D-CRT plans with opposing tangential beams were
planned to cover the PTV and a multi-leaf collimator
(MLC) was used, when necessary, to minimize the dose
delivered to the OARs. Beam energy was 6 MV; mixed en-
ergies (6 MV-10 MV) were occasionally used in larger
breasts. Wedges were used in almost all of the patients to
provide a homogenous PTV dose (95% of 50 Gy and
44 Gy for the CF and HS groups respectively). For each
patient, dose-volume histograms (DVHs) for the target
and OARs were obtained. Boost doses were delivering
using a 6–12 MeV electron fields. All patients were treated
using the Elekta PreciseW Accelerator (Elekta, Crawley,
United Kingdom).
Assessment of acute skin toxicity
Toxicity was described as the maximum reported acute
toxicity, either during or after completion of RT, as
described in the clinical records. Clinically evident skin
reactions (G2 – G3) were assessed using the RTOG Acute
Morbidity Scale defining grade G2 as tender or bright
erythema, patchy moist desquamation/moderate oedema,
Table 1 Main features of the 339 reported patients
Total patients (%) CF Patients (%) HS Patients (%) P Value
No. 339 141 (41.59) 198 (58.41)
Mean age (range) 60 (22–86) 52 (22–79) 62.5 (38–86) <0.001
Histology NS
ILC 30 (8.8) 12 (8.5) 18 (9.1)
IDC 299 (88.2) 126 (89.4) 173 (87.4)
Intraductal 10 (3) 3 (21) 7 (3.5)
T stage NS
T1 293 (86.4) 121 (85.8) 172 (86.7)
T2 46 (13.6) 20 (14.2) 26 (13.3)
N stage NS
Nx 21 (6,3) 8 (5,7) 13 (6,5)
N0 251 (74) 93 (65.9) 158 (79.8)
N1 67 (19.7) 32 (22.6) 35 (17.6)
Grading (Bloom Richardson’s scale) NS
G1 60 (17.7) 22 (15.6) 38 (19.2)
G2 131 (38.6) 58 (41.1) 73 (36.8)
G3 79 (23.3) 36 (25.5) 43 (21.7)
NA 69 (20.4) 25 (17.8) 44 (22.3)
Surgical margins NS
Negative 295 (87) 124 (87.9) 171 (86.4)
Positive 5 (1.5) 2 (1.4) 3 (1.5)
Close (< 2 mm) 27 (8) 10 (7.1) 17 (8.6)
Tangents 12 (3.5) 5 (3.6) 7 (3.5)
Breast Volume
Average cc 718.7 684 725.4 NS
(range) (188.6-2036.7) (188.6-1899.9) (193.3-2036.7)
Chemotherapy
Yes 126 (37.2) 68 (48.2%) 58 (29.3%)
No 211 (62.2%) 72 (51.1%) 139 (70.2%) 0.008
NA 2 (0.6%) 1 (0.7%) 1 (0.5%)
Hormone therapy
Yes 247 (72.8) 101 (71.6) 146 (73.7) NS
No 74 (21.8) 34 (24.1) 40 (20,2)
NA 18 (5.4) 6 (4.3) 12 (6.1)
Trastuzumab
Yes 17 (5) 7 (5) 10 (5) NS
No 327 (95) 134 (95) 188 (95)
CF: Conventional Fractionation; HS: Hypofractionated Schedule; ILC: infiltrating lobular carcinoma; IDC: infiltrating ductal carcinoma; NA: not available; NS: not
significant (P>0.05).
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than skin folds, pitting oedema. Grade G0 (no reaction)
and Grade G1 (faint reaction) were considered in a
common category as concerns the statistical evaluation of
the results.Dosimetry data collection
Our analysis took origin from the empirical observation
of the occurrence of G3 skin reactions in unexpected pa-
tients who did not show clinically detectable features
predicting adverse effects.
Table 2 Treatment and dosimetric characteristics in 200
patients whose plans were revaluated
CF: 79/141 (56%) HF: 121/198 (61,1%)
PTV (Gy) PTV (Gy)
Mean Dose: 50,17 Mean Dose: 44,16
Median Dose: 50,30 Median Dose: 44,39
V > 107% (cc) V > 107% (cc)
Mean Volume 10 Mean Volume 5.7
Median Volume 9 Median Volume 3
Mean Maximum Dose (Gy) 55,84 Mean Maximum Dose(Gy) 49,20
CF: Conventional Fractionation; HS: Hypofractionated Schedule.
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observed inhomogeneities of dose distribution which
were related to the higher skin toxicities appearing be-
fore or after the end of treatment. Following this obser-
vation, treatment plans were retrieved and revaluated
and a strong correlation was found between areas close
to the skin surface, with an inhomogeneity > 107% of
the prescribed dose, and the desquamation areas as
described in the clinical records. This quantitative dose-
volume analysis was performed in 200 patients repre-
senting more than 60% of all the patients with any
toxicity grade. We contoured, on each scan from the CT
planning within and outside the target, the Regions of
Interest (ROIs) corresponding to the areas receiving
a dose in excessive > 107% of the prescribed one
(> 53.5 Gy for CF and > 47.1 Gy for HS) which were
named V > 107 (cc) (Figure 1). The maximum doses,
over 107% of the prescribed ones, were also recorded.
Breast volume was estimated using volumetric measure-
ments of the planning target volume (PTV). Dosimetry
data are reported in Table 2.
“In vivo” measurements
During the first treatment sessions we used the
OneDosePlusTM MOSFET based as a dosimetric system
for “in vivo” measurements in order to measure the dose
actually delivered and to test the entire treatment pro-
cedure. Each MOSFET dosimeter was attached to the
patient’s skin with its build-up cap area at the projection
of the isocenter and as perpendicular as possible to the
beam central axis. These doses were compared with
those calculated with Precise Plan. For each patient, the
measurements were performed using one MOSFET for
each field of the treatment plan (both medial and lateral
fields). We calculated an Action Threshold (AT), definedFigure 1 Dose distribution in different breasts with and without mois
dry desquamation of the external upper quadrant. The V > 107% is located
patient with large breast not developing skin toxicity. The V > 107% is locaas the maximum acceptable discrepancy between the
dose measured with the detector and the dose calculated
with the TPS for each single field from phantom data
[12]. The AT was ± 5% within 2 Standard Deviations.
Statistical analysis
The χ2 and Mann–Whitney tests were used to compare
acute skin toxicity between different sample groups and
to analyze associations between acute toxicity, dosime-
tric parameters and clinical characteristics. Multivariate
analysis to independently predict the risk of acute skin
toxicity development was performed using binary logis-
tic regression. Statistical significance was assumed at p <
0.05; data were processed using the Statistical Package of
Social Sciences (SPSS) Version 17.0.
Results
Acute toxicity rates (Table 3) were found to be higher
among the patients undergoing CF (81.6%) with respect
to those treated with the moderate HS (62.6%) and the
difference, which is statistically significant (p < 0.001), is
not surprising.t desquamation. 1A Treatment plan of a patient developing moist
close to the skin surface (yellow arrow). 1B - Treatment plan of a
ted deeply in the breast parenchyma (yellow arrow).
Table 3 Frequency of any grade of acute skin toxicity between the two groups of patients
Total patients 339
CF HS P value
141 198
Patients Toxicity Patients Toxicity
(No.) grade (No.) grade
Acute Toxicity
239 115 G1: 52 (45,2%) 124 G1: 79 (63,5%)
< 0.001
G2: 36 (30%)
(81,6.%) G2: 48 (42%) (62,6%) G3: 9 (7,5%)
G3: 15 (13%)
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istered in 42% (48/115) and 13% (15/115) among the
patients who underwent irradiation with CF and in 30%
(36/124) and 7.5% (9/124) in the HS group respectively.
The onset of the peak skin toxicity, among the patients
undergoing conventional fractionation, appeared during
the last week of treatment (between session number 20
and 25) while, on the contrary, it appeared immediately
after the end of treatment among those undergoing
hypofractionated irradiation (around session number
16). For this reason the treatment was interrupted in 5
patients only and all of them belonged to the CF group,
but in none of those undergoing HF treatment. Eighty
percent of skin reactions occurred at the level of the
inframammary fold and the remaining ones in the upper
quadrants-axilla. G2-G3 skin reactions were always in
close proximity of an inhomogeneity of dose distribution
which was located under the skin surface. No skin reac-
tion was diagnosed in all of the patients in whom dose
inhomogeneity were deep in the breast tissue distant
from the skin.
Systemic treatments and patient and treatment related
factors of all of the 339 patients have been evaluated in a
univariate analysis (Table 4). Only age and fractionation
were found to be statistically significant as concerns the
occurrence of acute skin reaction (p < 0.001) whileTable 4 Univariate analysis: predictive factors for G1-G2-







(≤ average vs > average)
Breast Volume 0.072
(≤ average vs > average)
Fractionation Schedule < 0.001
(CF vs HS)
CF: Conventional Fractionation; HS: Hypofractionated Schedule.systemic treatments and volume of the breast did not
show any influence on the occurrence of acute adverse
effects (p = 0.80, p = 0.66 and p = 0.072 respectively for
chemotherapy, hormone treatment, breast volume). In
our analysis other clinical factors such as smoking,
hypertension, diabetes, were not significantly correlated
with the development of acute skin reaction. No topic
treatment was prescribed in any of these patients to pre-
vent or modify skin reaction.
The treatment plans of 200 patients, including approxi-
mately 60% of the patients belonging to the HS and CF
groups, were retrieved and revaluated and volumes recei-
ving more than 107% (V > 107%) of the prescribed dose
were defined in each single case. Half of these patients
showed no skin reaction (G0) or a very faint reaction (G1),
while the remaining belonged to the G2 – G3 groups.
At the univariate analysis, as summarised in Table 5,
younger age at diagnosis (p = 0.004), larger breast vol-
ume (p = 0.011), conventional fractionation (p < 0.001)
and V > 107% were related to an increased risk of G2 –
G3 skin reactions. Indeed, patients with no skin reaction
(G0) or faint limited erythema were found to have a
smaller V > 107% (3.9 cc ± 5.6 SD) in comparison to
those who presented a true skin reaction (G2 – G3)
whose V > 107% was, in average, 10.9 cc ± 8.7 SD. The
difference is statistically significant (p < 0.001). No sta-
tistically significant difference was highlighted, on the
contrary, for the maximum doses recorded in the ROIs.
At the multivariate analysis (Table 5) the only variable
retaining significance was V > 107% (p < 0.001) while frac-
tionation only showed a tendency towards significance in
favour of HS vs CF. The RR for patients with V > 107%
above the median value was 6 times higher than those
with V > 107% below the median value.
Figure 2 shows the number of patients with a volume
receiving more than V > 107% by grade of skin reaction:
hot spots are more represented among G2 – G3 pa-
tients. Plotting the data by the volumes receiving more
than V > 107% for the HF and CF respectively we obtain
a more detailed description of these results (Figure 3):
patients with higher values of V > 107% are evidently
more represented among those showing G2 and G3 skin
reactions.
Table 5 Univariate and multivariate analysis for G2-G3 radiation induced skin reactions in 200 patients
Variables
Univariate analysis Multivariate analysis
P Odds ratio (95% CI) P
Chemotherapy Yes vs No 0.054 1.137 (0.531-2.433) 0.741
Hormone Therapy Yes vs No 0.401 1.230 (0.547-2.765) 0.616
Fractionation Schedule CF vs HS < 0.001 2.045 (0.996-4.197) 0.51
V > 107% Mean ± SD < 0.001 6.335 (3.192-12.577) < 0.001
Age Mean ± SD 0.004 0.973 (0.943-1.005) 0.101
Breast Volume Mean ± SD 0.011 1.001 (1.000-1.002) 0.076
CI: confidence intervals; SD: standard deviation. CF: Conventional Fractionation;
HS: Hypofractionated Schedule.
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tinguishing between high and low risk of developing mild
to moderate or severe skin reaction has been found to be
3 cc for the HF patients and 9 cc for the CF ones
(Figure 3). Volumes, in cubic centimetres, receiving more
than 107% of the prescribed dose are larger among the CF
group (mean 10 cc and median 9 cc) than among the HF
patients (mean 5,7 cc and median 3 cc) (Table 2).
Discussion
Acute toxicity after treatment for breast cancer is an
issue which has been recently addressed in the literature
[3,4] and which deserves consideration as severe skin
toxicity can lead to temporary or permanent cessation of
treatment causing pain and maybe permanent skin
changes. After conservative surgery different fraction-
ation schemes have been introduced in the treatment of
breast cancer patients. With 5 and 10 years of follow-upFigure 2 Number of patients with any grade of skin reaction. On the
toxicity and on the y axis the volume V > 107% (cc). 2A - Patients with no
skin toxicity (G2-G3).the efficacy and cosmetic results of non conventional
fractionation schemes have been proven, in comparison
to the conventional ones, resulting in improved patient
convenience and decreased resource utilization [13-15].
Patients included in the aforementioned randomized tri-
als were predominantly treated with two dimensional
planning techniques, non-uniform use of inhomogeneity
corrections, and dose calculations limited to the central
axis. In the past decade there have been substantial shifts
in patterns of practice such that the 3D-CRT and IMRT
became widespread and have been proven beneficial in
improving dose homogeneity and reducing acute skin
toxicity in randomized trials [16,17]. In a recent study
Dorn and coll. have specifically examined dosimetric pa-
rameters and acute toxicity in patients with separation >
25 cm or large breast volume treated with HF. Their
rates of acute toxicity (8.7%) compare favourably with
those reported in other series of patients as well as withx axis is reported the number of patients showing any grade of skin
or faint skin toxicity (G0-G1). 2B - Patients with moderate to severe
Figure 3 Distribution of acute skin reactions in patients undergoing different fractionation and median V > 107 cut-off value.
3A – Hypofractionation group where most of patients with G0- G1 reactions belong to the median cut-off V > 107% value < 3 cc. 3B – Conventional
fractionation group where most of patients with G0- G1 reactions belong to the median cut-off V > 107% value < 9 cc.
Tortorelli et al. BMC Cancer 2013, 13:230 Page 7 of 9
http://www.biomedcentral.com/1471-2407/13/230the data in our series (G3 13% and 7.5% respectively in
the CF and HF patients) [8].
In our series (339 patients) the only factors associated
with any grade of skin toxicity at a univariate analysis were
age at diagnosis and fractionation. Breast volume, systemic
treatments and other patient related factors did not show
any influence on the occurrence of skin toxicity.
As concerns breast volume as a relevant factor related
to skin toxicity contradictory data are available in the lit-
erature. Recently two papers [18,19] reach opposite con-
clusions. Corbin et al. [18] state that among obese and
large breasted women (> 1500 cm3), in their experience,
there was no increase in acute skin toxicity in the group
undergoing hypofractionated radiation therapy. On the
contrary Kraus-Tiefenbacher et al. [19] state that one of
the factors associated with higher grade skin toxicity
was, in their experience, the presence of larger breast
volumes (range 402–4283 cc, median 946,9 cc). One
possible explanation for these discrepancies may be that
different criteria have been used to define what is con-
sidered “a large breast”. Freedman et al. [20] found a
positive correlation between breast size and skin toxicity
in larger breast volumes defined as > cup D. Vicini et al.
[21] found that patients with breast volume > 1600 cc
had more acute skin toxicity compared to those with
smaller breast volumes (< 1000 cc). Another report [22]
showed no G3 RTOG acute effect with breast volumes <
975 cc while patients with breast volumes greater then
1600 cc developed 59% RTOG G2 and 3% G3 erythema.
As in our evaluation they measured breast volume in
analogy to our method (manually contouring of breast
target volume). The average breast volumes among our
patients are smaller (718.7 cc, range between 188.6 cc
and 2036.7 cc) than those reported in the previous pa-
pers. Even as concerns the role of systemic treatments
before external beam radiation therapy on skin toxicitythe data in the literature are contradictory. There are a
few studies where a significant correlation between chemo-
therapy and increased skin toxicity was documented
[21,22]. Different results have on the contrary been pub-
lished [23,24] showing a trend to increase higher grade skin
toxicity after chemotherapy.
Our statistical analysis was performed on 200 patients
whose 3D-CRT were retrieved and revaluated to better
define site and size of homogeneities of dose distribution
and its relation with the site of the skin damage. We
decided to revaluate the entire 3D plan, instead of
relying only on the DVHs of the single patient which
does not allow to locate the site of the dose inhomoge-
neities > 107% which we consider relevant to the de-
velopment of acute skin toxicity. Among these patients
age, type of fractionation (CF vs HS), breast volume and
inhomogeneity of dose distribution (V > 107%) were sta-
tistically significant at the univariate analysis and corre-
lated with skin reaction. On multivariate analysis, on the
contrary, there was only an association between the het-
erogeneity parameter V > 107% and skin reaction which is
not unexpected.
In two randomized trials [25,26] comparing IMRT to
two-dimensional breast planning, improved homogeneity
translated into reductions in acute toxicity supporting the
need that an accurate evaluation of dose homogeneity,
before treatment delivery, may reduce acute severe skin
reactions.
IMRT may obtain a better dose distribution and a re-
duction of dose inhomogeneities, but it is more time
consuming as concerns planning and delivery and it is,
of course, more expensive. As the number of patients
deserving a more complex treatment is limited to those
at risk for severe skin damage, who are approximately
less than 10% of all of the patients undergoing postoper-
ative irradiation for breast cancer, IMRT should be
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bution showing dose inhomogeneities greater than 107%
of the prescribed dose.
As concerns age we underline that, at least in our series,
it is unrelated to skin toxicity in spite of the significance
obtained at univariate analysis (p = 0.001). At the begin-
ning of our experience we selected, in fact, older patients
to undergo treatment with the HF schedule and this selec-
tion has probably introduced a bias in the analysis.
Dosimetric analyses in the aforementioned randomised
trials [13-15] were mainly performed at the central axis
and therefore no information were available on the off-
axis target volume and on site and size of hot spots and
dose inhomogeneities. In this analysis off-axis heterogen-
eity was evaluated on the retrieved and revaluated 3-D
plans allowing a clear definition of the site and size of
the hot spots. Inhomogeneities were found to be signifi-
cant and on multivariate analysis they were found to be
the only factor retaining statistical significance [OR: 6.3
(95% CI: 3.192 - 12.577); p < 0.001]. The Odd Ratio for
V > 107% is six times higher than that calculated for sys-
temic therapies, age and breast volume, and three times
higher than that related to fractionation supporting the
strong relation between dose inhomogeneity and acute
severe skin reaction.
The retrieval of the treatment plans allowed, moreover,
an evaluation of the relation between the site of the hot
spots and the occurrence of skin reaction. Hot spots
were more frequent than skin reactions due to the fact
that only inhomogeneities close to the skin surface were
responsible of skin reactions which were consistent with
the description of the site and size of moist desquam-
ation reported in the clinical records. Hot spots deep
seated in the breast parenchyma may probably contrib-
ute to the occurrence of different types of acute or late
toxicities, but do not contribute, in our experience, to
severe skin acute damage.
In our series skin toxicity appeared always immediately
before or concomitant to the end of the treatment on
the entire breast and always before the boost irradiation
of the tumor bed excluding any role or responsibility of
the boost as concerns the occurrence of the reaction.
Data from the literature and from our series show that
dose inhomogeneities may be responsible for acute skin
damage while the role of different patient or tumor related
factors, other than breast volume, are not common to all
of the reported experiences in the literature. Recently the
attention has been focused on the fact that mismatch
repair mechanisms may be involved in cellular response
to RT and genetic polymorphisms [27] may be candidates
for predicting acute radiosensitivity and we believe that
further studies evaluating this hypothesis may contribute
to a better comprehension of the steps leading to the oc-
currence of severe acute skin reactions.Conclusions
In conclusion:
1. The proportion of patients expected to experience
high grade skin toxicity is on the order of 10 - 15%
among HF patients and such rates compare
favourably with those reported in our series (G3 13%
and 7.5% respectively in the CF and HF patients)
supporting the use of HF in the treatment of
patients after BCS without any risk of increasing
acute skin damage;
2. HF after BCS is safe and feasible and a shorter
course of treatment in a broader range of patients
may improve patient convenience and decrease
resource utilization;
3. with the limits of a retrospective study our results
suggests that dose inhomogeneties (V > 107%) have
a significant impact on the occurrence of severe skin
reactions as pointed out by Chen and coll. [7] too
who demonstrated that a larger volume receiving >
53.9 Gy, within PTV (PTV - V107%), was a
significant predictor of RT- induced skin toxicity;
4. deep seated dose inhomogeneities, which do not
correlate with skin reaction, deserve particular
attention to detect other types of side effects which
have not yet been investigated and reported in the
aforementioned randomized trials;
5. increasing interest is arising around the possibility
that genetic polymorphisms may be candidates for
predicting acute radiosensitivity and this aspect
deserves attention and has to be investigated.
Appendix
n: total number of fractions
d: size of fractions in Gy
T: overall time of treatment (days, with first day as D0)
Tk: onset (kick-off ) time of repopulation in the tissue
of interest: 21 days
Tp: potential doubling time of cancer repopulating
cells: 3 days
α: radiosensitivity coefficient of non-recoverable dam-
age: 0.35
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